» Articles » PMID: 20045719

Dysfunction of Dopamine Release in the Prefrontal Cortex of Dysbindin Deficient Sandy Mice: an in Vivo Microdialysis Study

Overview
Journal Neurosci Lett
Specialty Neurology
Date 2010 Jan 5
PMID 20045719
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Dystrobrevin binding protein-1 gene (DTNBP1), which encodes dysbindin protein, has been identified as a schizophrenia susceptibility gene. Dysbindin has been shown to contribute to the regulation of exocytosis and formation of synaptic vesicles. Although hypofrontality in schizophrenia underlies its pathophysiology, the molecular function of dysbindin in synaptic neurotransmission remains unclear. In the present study, we investigated depolarization-evoked dopamine (DA) and serotonin (5-HT) release in the prefrontal cortex (PFC) of sandy (sdy) mice, which have a deletion mutation in the gene encoding DTNBP1. In vivo microdialysis analysis revealed that extracellular DA levels in the PFC of wild-type mice were increased by 60mM KCl stimulation, and the KCl-evoked DA release was significantly decreased in sdy mice compared with wild-type mice. Extracellular 5-HT levels in the PFC of wild-type mice were also increased by 60mM KCl stimulation. The KCl-evoked 5-HT release did not differ between wild-type and sdy mice. There was no difference in basal levels of DA and 5-HT before the stimulation between two groups. Behavioral sensitization after repeated methamphetamine (METH) treatment was significantly reduced in sdy mice compared with wild-type mice whereas no difference was observed in METH-induced hyperlocomotion between two groups. These results suggest that dysbindin may have a role in the regulation of depolarization-evoked DA release in the PFC and in the development of behavioral sensitization induced by repeated METH treatment.

Citing Articles

Dysbindin-1 Mutation Alters Prefrontal Cortex Extracellular Glutamate and Dopamine In Vivo.

Szumlinski K, Datko M, Lominac K, Jentsch J Int J Mol Sci. 2024; 25(23).

PMID: 39684450 PMC: 11640900. DOI: 10.3390/ijms252312732.


Neurobiological effects of gallic acid: current perspectives.

Bhuia M, Rahaman M, Islam T, Bappi M, Sikder M, Hossain K Chin Med. 2023; 18(1):27.

PMID: 36918923 PMC: 10015939. DOI: 10.1186/s13020-023-00735-7.


The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study.

DAmbrosio E, Dahoun T, Pardinas A, Veronese M, Bloomfield M, Jauhar S Psychiatry Res Neuroimaging. 2019; 291:34-41.

PMID: 31386983 PMC: 7099976. DOI: 10.1016/j.pscychresns.2019.07.005.


Genetic and animal model analyses reveal the pathogenic role of a novel deletion of RELN in schizophrenia.

Sobue A, Kushima I, Nagai T, Shan W, Kohno T, Aleksic B Sci Rep. 2018; 8(1):13046.

PMID: 30158644 PMC: 6115412. DOI: 10.1038/s41598-018-31390-w.


Protective effect of gallic acid in experimental model of ketamine-induced psychosis: possible behaviour, biochemical, neurochemical and cellular alterations.

Yadav M, Jindal D, Dhingra M, Kumar A, Parle M, Dhingra S Inflammopharmacology. 2017; 26(2):413-424.

PMID: 28577133 DOI: 10.1007/s10787-017-0366-8.